BioCryst Pharmaceuticals, Inc. (BCRX) News
Follow BioCryst Pharmaceuticals, Inc. (BCRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Undervalued healthcare stocks with attractive valuation grades
Healthcare stocks continue to attract investor attention as managed care providers, pharmaceutical companies, biotechnology firms and healthcare services businesses navigate changing demand and industry conditions.With v
NEWS | Sep 15, 2026, 05:21 PM UTC
L
BCRX: External innovation and disciplined growth drive rare disease portfolio expansion and profitability
A shift to external innovation and strategic acquisitions is driving pipeline expansion and profitability, with ORLADEYO and navenibart positioned for complementary growth. The company targets rare diseases with strong s
NEWS | Sep 15, 2026, 03:08 PM UTC
L
BCRX: External innovation and product diversification drive growth toward a $1B+ rare disease portfolio
The company is shifting from internal discovery to external innovation, aiming for three marketed products and over $1 billion in revenue by 2030. ORLADEYO continues to drive growth, with new pediatric indications and st
NEWS | Sep 15, 2026, 02:24 PM UTC
L
RBC Capital downgrades BioCryst to Sector Perform
BioCryst Pharmaceuticals (BCRX) came under scrutiny after RBC Capital said the company faces a “challenging near-term outlook,” following strong late-stage data from Pharvaris (PHVS) for hereditary angioedema therapy. RB
EQUITY | Sep 10, 2026, 03:52 PM UTC
L
RBC Capital cuts BioCryst Pharmaceuticals price target to $11
EQUITY | Sep 10, 2026, 02:46 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
M
BCRX sinks 9% after competitor reports strong hereditary angioedema results
BioCryst Pharmaceuticals shares fell sharply Tuesday, dropping 9%. The selloff follows a competitor’s strong late-stage results in hereditary angioedema, the rare swelling disorder behind BioCryst’s main product.
EQUITY | Sep 08, 2026, 11:24 PM UTC
L
Needham maintains $16.00 price target on BioCryst Pharmaceuticals
Needham maintained a $16.00/share price target for BioCryst Pharmaceuticals, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 05:42 PM UTC
L
BioCryst to present at Morgan Stanley healthcare conference
BioCryst Pharmaceuticals plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
BioCryst (BCRX) to present at upcoming investor conference
BioCryst says it will present at an upcoming investor conference.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
EQUITY | Aug 28, 2026, 11:40 PM UTC
M
BioCryst (BCRX) wins Japan approval for ORLADEYO® pediatric HAE patients
BioCryst announces approval of ORLADEYO® for pediatric HAE patients in Japan, expanding the company’s approved use in that market.
EQUITY | Aug 25, 2026, 11:01 AM UTC
L
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est
BioCryst Pharma (NASDAQ: BCRX ) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.
EARNINGS | Aug 05, 2026, 11:05 AM UTC
L
BCRX - BioCryst Reports Second Quarter 2026 Financial Results
BCRX - BioCryst Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
BCRX Biocryst appoints David W. Jenkins as chief Scientific officer
BCRX Biocryst appoints David W. Jenkins as chief Scientific officer
EQUITY | Jul 15, 2026, 11:01 AM UTC
L
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ: BCRX ) with a Buy and maintains $32 price target.
EQUITY | Jun 30, 2026, 02:35 PM UTC
L
Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ: BCRX ) with a Overweight and raises the price target from $27 to $29.
EQUITY | Jun 30, 2026, 12:05 PM UTC
H
BioCryst Shifts Pipeline Strategy, Reaffirms Sales Outlook Of $635.00M-$660.00M Vs 670.47M
BioCryst shifts pipeline strategy, discontinues internal discovery programs.
EQUITY | Jun 29, 2026, 11:13 AM UTC